Alkem Launches 'PRAYAS': A Bold Step Toward Accessible Cancer Care
In a significant patient-centric move, Alkem Laboratories Ltd., one of India's largest pharmaceutical companies, has launched PRAYAS- a dedicated Patient Assistance and EMI Support Program aimed at improving access to life-saving biosimilars for cancer patients across the country.
PRAYAS is currently being rolled out for patients requiring Bevacizumab 100mg and 400mg with brand name ADVAMAB, a key therapy in multiple cancers, including colorectal, ovarian, and non-small cell lung cancer, among others. The program offers:
- 0% Interest EMI Options – Enabling timely initiation and continuation of therapy
- Need-Based Financial Assistance – For patients from low-income backgrounds
- Customizable Support – Vial support, financial aid, or both depending on patient profile
Enrollment into the PRAYAS program is simple and accessible—patients or caregivers can write to prayas@rxcs.in, call the dedicated helpline at +91 9240205435, or register via the online portal at https://leads.icanheal.in/alkem
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.